Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Chuikyo OKs Listing of Mounjaro, Libtayo, Imjudo; 30 Billion-Plus Peak Sales for Lilly Med
The Central Social Insurance Medical Council (Chuikyo) on March 8 approved a batch of medicines for their reimbursement listing on March 15, with Eli Lilly’s diabetes drug Mounjaro (tirzepatide) boasting the biggest peak sales projection among them, at over 30…
To read the full story
Related Article
- LEO Pharma’s Eczema Drug Adtralza Now Available in Japan
September 27, 2023
- Ohara’s Cancer Med Erwinase Reaches Japan Market Over 6 Years after Approval
June 15, 2023
- Lilly, Mitsubishi Tanabe Roll Out Mounjaro’s High-Dose Versions
June 13, 2023
- Lilly’s Mounjaro Hits Japan Pharmacy Shelves, Mitsubishi as Distributor
April 19, 2023
- Radicut Oral Form Now Available for ALS Patients in Japan: Mitsubishi Tanabe
April 18, 2023
- Sanofi Launches PD-1 Inhibitor Libtayo in Japan
March 31, 2023
- Xocova to Be Commercially Available from March 31
March 24, 2023
- Iron Solution MonoVer Now Available in Japan; Donepezil Patch, Cresemba to Hit Market in April
March 16, 2023
- AbbVie’s Parkinson’s Drug, Kaken’s Eschar Remover Skip March Listing
March 9, 2023
- Japan Approves Sanofi’s PD-1 Inhibitor, Teikoku’s Donepezil Tape and More
December 26, 2022
- Japan Approves Mounjaro, Tezspire, Fintepla, Label Expansions for Rinvoq/Skyrizi, Keytruda, and More
September 27, 2022
- Ohara’s High-Need Pediatric Cancer Drug in Limbo 2 Years after Approval due to GMP Issue
February 15, 2019
REGULATORY
- Japan Urges Priority Supply of Petroleum-Based Materials for Medical Devices
March 31, 2026
- Japan’s New HIV Cases Hit 20-Year Low in 2025
March 30, 2026
- MHLW Launches Genomic Medicine Body GeMJ
March 30, 2026
- TNF Inhibitors, Cancer Drugs Flagged in PMDA Risk Review
March 30, 2026
- Japan Ranks 9th Among 10 in AI Analysis of EFPIA Pharma Strategy Report
March 27, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…